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Abstract: Our group has demonstrated that inflammatory 
diseases such as type 2 diabetes (DM), inflammatory bowel 
disease (IBD), and periodontal disease (PD) are associated with 
altered B cell function that may contribute to disease 
pathogenesis.  B cells were found to be highly activated with 
characteristics of inflammatory cells.  Obesity is a pre-disease 
state for cardiovascular disease and type 2 diabetes and 
is considered a state of chronic inflammation. Therefore, we 
sought to better characterize B cell function and phenotype in 
obese patients. We demonstrate that (Toll-like receptor) TLR4 
and CD36 expression by B cells is elevated in obese subjects, 
suggesting increased sensing of lipopolysaccharide (LPS) and 
other TLR ligands.  These ligands may be of microbial, from 
translocation from a leaky gut, or host origin.  To better assess 
microbial ligand burden and host response in the bloodstream, we
measured LPS binding protein (LBP), bacterial/permeability 
increasing protein (BPI), and high mobility group box 1 (HMGB1).
Thus far, our data demonstrate an increase in LBP in DM and 
obesity indicating increased responses to TLR ligands in the 
blood.  Interestingly, B cells responded to certain types of LPS by 
phosphorylating extracellular-signal-regulated kinases (ERK) 1/2.   
A better understanding of the immunological state of obesity and
the microbial and endogenous TLR ligands that may be activating 
B cells will help identify novel therapeutics to reduce the risk of 
more dangerous conditions, such as cardiovascular disease. 
Methods: An obesity related insulin resistant population with a 
body mass index (BMI) over 30 with varying degrees of insulin 
resistance but non-diabetic were included. Also included were 
healthy volunteers with no clinical symptoms of chronic 
inflammatory disease designated “healthy,” and a subset of 
healthy volunteers designated “leans” with a BMI of <26. 
Heparinized whole blood was incubated with fluorescently-
labeled antibodies.  Assessment of surface expression on B cells 
was performed with gates generated with anti-CD19 + the 
appropriate isotype controls for each sample. Serum samples
were assayed for protein by standard ELISA.  LPS was 
measured in the serum with Limulus Amebocyte Lysate assay.
Conclusions: We conclude that there 
is an increased expression of TLR4 on 
the surface of B cells from obese 
patients along with an increase in 
CD36, an accessory receptor for TLRs.   
An increase in LBP levels in obese 
patients suggests increased microbial 
activity in the blood of patients with a 
non-infectious disease. B cells are 
responsive to LPS but to unexpected 
types of LPS suggesting that B cells 
may have an alternative role in sensing 
LPS compared to other cells such as 
macrophages. The clinical relevance of 
ERK 1/2 phosphorylation following 
RsLPS stimulation of B cells is under 
investigation.  These data support the 
hypothesis that altered B cell function 
and increased microbial ligand load 
may play a role in the inflammation 
seen in chronic inflammatory diseases. 
Because B cells respond to 
unexpected microbial ligands, 
understanding the composition of 
bacteria in blood and which bacteria 
affect B cells, may allow us to 
understand the pathogenesis of LPS in 
insulin resistance and develop targeted 
interventions. 
Results:
-TLR4 expressing B cell percentages were higher in DM and obese patients (Figure 1).  
-TLR4 expression did not correlate with BMI.  
-There was a significant increase in serum LBP levels in obese and DM patients (Figure 2). 
-B cells from obese patients have increased CD36 expression, an accessory receptor for TLRs 
(Figure 3).   
-TLR4+ B cells responded to stimulation by hypo-acylated Rhodobacter sphaeroides LPS (RsLPS) 
by phosphorylating ERK1/2 (Figure 4). 
Figure 5. The Blood Microbiome Construct, BU 
Department of Medicine. The presence of 
microbial ligands in the blood may be explained by 
a leaky gut, and may trigger the inflammation seen 
in chronic inflammatory diseases. Image created 
by Susan Fried, PhD; Marie McDonnell, MD and 
Lisa Ganley-Leal, PhD.
ERK1/2
Figure 4. B Cell Signaling TLR4+ B cells exhibit ERK1/2 
phosphorylation 10 minutes post-stimulation with RsLPS.
Figure 1.  Percentage TLR4+ B cells. TLR4 expression on 
B cells is significantly higher in DM and obese patients 
(n=113, P<.0001).  The horizontal bars on the graph 
indicates median.
TLR4 B cell
DM Obese Healthy
0
25
50
75
100
P
e
r
c
e
n
t
 
T
L
R
4
+
 
 
B
 
c
e
l
l
Figure 2. Serum LBP Levels in DM, Obese, and Lean 
Patients. LBP levels were significantly higher in DM and 
obese patients compared to lean patients (n=27, P=.0022).  
The horizontal bars on the graph indicate medians.
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Figure 3. Mean Comparison of the Percentage of CD36+ 
B Cells. There is a significant increase in percentage of 
CD36 expressing B cells in T2D and obese patients in 
comparison to healthy subjects (n=21, P=.0016).  There is 
also a statistically significant difference in variances 
(P=.0220).
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